{"classes":[{"categories":[{"measurements":[{"comment":"A standard deviation was not calculated for a single participant.","groupId":"OG000","spread":"NA","value":"190"},{"comment":"A standard deviation was not calculated for a single participant.","groupId":"OG001","spread":"NA","value":"68.8"},{"comment":"A standard deviation was not calculated for a single participant.","groupId":"OG002","spread":"NA","value":"1010"},{"groupId":"OG003","spread":"116","value":"641"},{"groupId":"OG004","spread":"498","value":"1140"},{"groupId":"OG005","spread":"1210","value":"1820"},{"groupId":"OG006","spread":"935","value":"2510"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"21"},{"groupId":"OG005","value":"69"},{"groupId":"OG006","value":"69"}],"units":"Participants"}],"description":"AUClast was defined as the area under the plasma or serum concentration-time curve from the time of dosing to the last measurable concentration.","dispersionType":"Standard Deviation","groups":[{"description":"Participants self-administered oral pemigatinib 1 milligram (mg) once daily (QD) on a 2-weeks-on therapy and 1-week-off therapy schedule in Part 1. The treatment cycle consisted of: Days 1 through 14: pemigatinib QD; Days 15 through 21: treatment break.","id":"OG000","title":"Part 1: Intermittent Pemigatinib 1 mg QD"},{"description":"Participants self-administered oral pemigatinib 2 mg QD on a 2-weeks-on therapy and 1-week-off therapy schedule in Part 1. The treatment cycle consisted of: Days 1 through 14: pemigatinib QD; Days 15 through 21: treatment break.","id":"OG001","title":"Part 1: Intermittent Pemigatinib 2 mg QD"},{"description":"Participants self-administered oral pemigatinib 4 mg QD on a 2-weeks-on therapy and 1-week-off therapy schedule in Part 1. The treatment cycle consisted of: Days 1 through 14: pemigatinib QD; Days 15 through 21: treatment break.","id":"OG002","title":"Part 1: Intermittent Pemigatinib 4 mg QD"},{"description":"Participants self-administered oral pemigatinib 6 mg QD on a 2-weeks-on therapy and 1-week-off therapy schedule in Part 1. The treatment cycle consisted of: Days 1 through 14: pemigatinib QD; Days 15 through 21: treatment break.","id":"OG003","title":"Part 1: Intermittent Pemigatinib 6 mg QD"},{"description":"Participants self-administered intermittent or continuous oral pemigatinib 9 mg QD in either Part 1 or Part 2. Intermittent dosing: participants self-administered oral pemigatinib 9 mg QD on a 2-weeks-on therapy and 1-week-off therapy schedule in either Part 1 or Part 2. The treatment cycle consisted of: Days 1 through 14: pemigatinib QD; Days 15 through 21: treatment break. Continuous dosing: participants self-administered oral pemigatinib 9 mg QD on Days 1 through 21 of each 21-day cycle in either Part 1 or Part 2.","id":"OG004","title":"Parts 1 and 2: Intermittent/Continuous Pemigatinib 9 mg QD"},{"description":"Participants self-administered intermittent or continuous oral pemigatinib 13.5 mg QD in either Part 1 or Part 2. Intermittent dosing: participants self-administered oral pemigatinib 13.5 mg QD on a 2-weeks-on therapy and 1-week-off therapy schedule in either Part 1 or Part 2. The treatment cycle consisted of: Days 1 through 14: pemigatinib QD; Days 15 through 21: treatment break. Continuous dosing: participants self-administered oral pemigatinib 13.5 mg QD on Days 1 through 21 of each 21-day cycle in either Part 1 or Part 2.","id":"OG005","title":"Parts 1 and 2: Intermittent/Continuous Pemigatinib 13.5 mg QD"},{"description":"Participants self-administered intermittent or continuous oral pemigatinib 20 mg QD in either Part 1 or Part 2. Intermittent dosing: participants self-administered oral pemigatinib 20 mg QD on a 2-weeks-on therapy and 1-week-off therapy schedule in Part 1. The treatment cycle consisted of: Days 1 through 14: pemigatinib QD; Days 15 through 21: treatment break. Continuous dosing: participants self-administered oral pemigatinib 20 mg QD on Days 1 through 21 of each 21-day cycle in either Part 1 or Part 2.","id":"OG006","title":"Parts 1 and 2: Intermittent/Continuous Pemigatinib 20 mg QD"}],"paramType":"MEAN","populationDescription":"PK/PD Population. Only participants with available data were analyzed.","reportingStatus":"POSTED","timeFrame":"Part 1: predose; 0.5, 1, 2, 4, 6, and 8 hours post-dose post-dose on Cycle 1 Day 1. Part 2: predose on Cycle 1 Day 1","title":"Parts 1 and 2: AUClast After Once Daily Dosing of Pemigatinib as Monotherapy on Cycle 1 Day 1","type":"SECONDARY","unitOfMeasure":"hr*ng/mL"}